

Artigo / Article

Maturation of dendritic cells following exposure to different maturational stimuli**Maturação das células dendríticas após exposição a diversos estímulos**

Aparecida M. Fontes¹
Maristela D. Orellana²
Patricia V.B. Palma³
Dimas T. Covas⁴

Dendritic cells (DCs) are professional antigen-presenting cells that are highly effective to immunize against pathogens and tumor antigens. In order to obtain mature DCs several *in vitro* methods have been reported. Selecting the most efficient and effective method of generating morphologic and phenotypic DCs within 7 days of culture is an essential prerequisite for success in immunotherapy strategies. Herein, we report a method of obtaining an enriched monocyte population from blood donors and performed a comparison of DC maturation in response to four agents. Monocyte populations with 91% \pm 5 of purity were obtained from 15 healthy donors. The resulting monocyte populations were cultured in the presence of GM-CSF and IL-4 during 5 days. At day 5 different maturation conditions were performed and morphological and phenotypical changes were analyzed. Our study demonstrates that TNF- α or PGE₁ by themselves can induce the expression of CD1a 2.4 and 2.7 times respectively more than DC cultures in the absence of maturing agents. On the other hand, for other costimulatory or accessory molecules (CD80, CD86, CD83 and CD40) TNF- α was more potent in the induction of expression than PGE₁, although in the presence of TNF- α plus PGE₁ this effect is more pronounced compared to TNF- α alone. Under TNF- α plus PGE₁ treatment the phenotypical maturation of immature DCs are comparable to LPS and therefore TNF- α + PGE₁ might be useful for generating *ex vivo* DCs to use in protocols of cell vaccination. Further functional evaluation of these mature DCs is warranted. Rev. bras. hematol. hemoter. 2006;28(2):89-96.

Key words: Dendritic cells; monocytes; Percoll; maturation; immunotherapy.

Introduction

Dendritic cells (DCs), which were discovered more than 25 years ago, are the most potent members in the class of antigen-presenting cells (APCs) and are initiators and modulators of the immune response. They are mobile sentinels that bring antigens to T-cells and express costimulators for the induction of immunity.^{1,2} The exceptional ability of DCs to stimulate T-cells *in vivo* is attributed to their dichotomous nature, as immature and mature DCs. Immature DCs (iDCs), exist in peripheral tissues, where they continuously capture and process antigens, but they

are relatively poor stimulators of T-cell responses. Upon exposure to inflammatory cytokines, iDCs upregulate costimulatory molecules and chemokine receptors. The first are required for the activation of antigen-specific T-cells, which takes place in the T-cell region of draining lymph nodes and the second are required for their migration to the lymph nodes. The mature dendritic cells (mDC) express a unique repertoire of cell-surface molecules including high levels of: a) molecules involved in antigen presentation to T-cells, such as, MHC class I, MHC class II and CD1a; b) adhesion molecules, such as, ICAM-1 (CD54), LFA-3 (CD58), Mac-1a (CD11c), SIRP-1a (CD172), VLA-4a

¹PhD - Doutorado em Biologia Celular e Molecular FMRP/USP e Pós-doutorado no Deptº Hematologia/Oncologia da CWRU/ Cleveland, OH, USA.

²Mestre em Imunologia Básica - IB/Unicamp - Campinas-SP.

³Bióloga PUC/Campinas-SP.

⁴PhD - Professor associado do Deptº de Clínica Médica da Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo FMRP/USP.

Correspondence: Dimas T. Covas
Centro Regional de Hemoterapia de Ribeirão Preto - HC-FMRP/USP
14051-140 - Ribeirão Preto -SP - Brazil
Tel: 55-16-21019300 - Fax: 55-16-21019309
E-mail: dimas@fmrp.usp.br

(CD49d) and VLA-5a (CD49e); c) costimulatory and accessory molecules, for example, B7-1 (CD80), B7-2 (CD86), CD40 and CD83 and d) chemokines receptors, such as, CCR7 and CXCR4.^{3,4}

The key role of DCs in the initiation of immune responses has focused the attention of many investigators on the potential efficacy of these cells in tumor immunotherapy,^{5,6} for antiviral CTL responses⁷ and for anti-infection response for common intracellular pathogens such as leishmaniasis, histoplasmosis and mycobacterial species.⁸⁻¹⁰

The focus of our laboratory is to develop a very efficient and effective method of generating morphologic and phenotypic DCs within short periods to allow their use in cancer immunotherapy.

In developing strategies to optimize the use of dendritic cell-based immunotherapy in humans, several experimental methods have been reported.¹¹⁻¹³ At present, most of the clinical trials use DCs generated from monocytes based on the findings of Sallusto and Lanzavechia,¹⁴ which consist in the generation of mature DCs by culturing peripheral blood mononuclear cells in the presence of GM-CSF plus interleukin 4 (IL-4) for one week followed by stimulation with TNF- α for 48h. GM-CSF is a growth factor for stem cells from granulocyte and macrophage lineages¹⁵ and in DC cultures it appears to increase the expression of class II major histocompatibility complex (MHC) antigens, enhancing the antigen presenting capacity of DCs. IL-4 inhibits both granulocyte and macrophage development and it seems to keep DCs in an "immature" state, thus more capable of processing exogenous antigens. TNF- α in DC cultures appears to inhibit the granulocyte maturation and promotes the maturation of DCs to a state where they lose their ability to process antigens but are very active in stimulating naive lymphocytes.

As maturation is an essential part of DC function increasing effort has been devoted to study other maturation stimuli. Some other DC maturation stimuli include microbial products (e.g., lipopolysaccharide LPS,¹⁶⁻¹⁷ prostaglandin E (PGE,¹⁸⁻¹⁹), CD40 ligand²⁰ and several combinations of these molecules have been used for *ex vivo* generation of mature DCs.^{13,21-23}

It is well-established in these studies that exogenous prostaglandins E₂ or E₁ can enhance the TNF- α -induced maturation in DCs as analysed by morphology, phenotype, ability to stimulate the allogeneic mixed leukocyte reaction, and induction of IL-12 production,^{13,19,24} but a systematic comparison of the phenotypical maturation of DCs generated from normal volunteers has not been performed yet.

In this study we performed a comparative study among four different DC maturation agents to investigate the influence of proinflammatory factors (TNF- α and PGE₁) in isolation or TNF- α in combination with PGE₁, as well as

bacterial products (LPS) in the expression of each molecule characteristic of mature DCs, including CD1a, CD80, CD86, CD83 and CD40 evaluated by flow cytometry. Also, the characteristics of DCs were determined by evaluating their morphology by light microscopy. Our study demonstrates that TNF- α or PGE₁ by itself can increase the CD1a expression by 2.4 and 2.7 times, respectively, more than DC cultures in the absence of maturing agents. On the other hand, for other costimulatory or accessory molecules (CD80, CD86, CD83 and CD40) TNF- α was more potent to induce the expression compared to PGE₁, although in the presence of TNF- α plus PGE₁ this effect is more pronounced compared to TNF- α alone. Under TNF- α plus PGE₁ treatment the phenotypical maturation of immature DCs are comparable to LPS.

Materials and Methods

Cell culture media and recombinant cytokines

In all experiments, we used the complete RPMI-1640 (Sigma Chemical Company; St Louis, MO) medium supplemented with 10% heat-inactivated fetal bovine serum (Hyclone laboratories, Logan, UT), 2 mmol/l L-glutamine, 100 U/ml penicillin, 100 μ g/ml streptomycin (all from Gibco-BRL). Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human interleukin-4 (IL-4), tumor necrosis factor- α (TNF- α), prostaglandin-E₁ and lipopolysaccharide (LPS) were all purchased from Sigma (Sigma Chemical Company; St Louis, MO).

Percoll gradient

The 50% Percoll gradient (density 1.064 g/ml) as described by Almeida²⁵ was used with one modification. First the isosmotic Percoll solution was prepared with one volume of PBS 10X (137 mM NaCl, 2.6 mM KCl, 8.45 mM Na₂HPO₄ and 1.52 mM KH₂PO₄) and nine volumes of Percoll (Pharmacia, density 1.130 g/ml), afterwards the 50% Percoll solution was prepared by mixing 1:1 (v/v) isosmotic Percoll: PBS1X plus 0.6% ACDA.

Experimental design

DCs were generated from leukocyte-enriched Buffy coats. The Buffy coat, derived from 500 ml of whole blood drawn from a healthy volunteer, was supplied by the Blood Fractionation Laboratory of Regional Blood Center of Ribeirão Preto, in compliance with institutional guidelines and immediately processed. The leukocyte-enriched Buffy coats were diluted twice in PBS and the purification of high-enriched monocyte population was obtained as follows: first the mononuclear cells were purified by Ficoll-Hypaque gradient (Pharmacia, density 1.077 g/ml) and centrifuged at 700 g for 30 min at room temperature. Afterwards, the MNCs were washed twice with PBS (final volume 20 ml)

and centrifuged into 20 ml of 50% Percoll solution at 400 g for 35 min at room temperature. The cells from the interface were collected, washed twice with PBS and the number of cells counted. The purity of monocyte population was evaluated by flow cytometry using an anti-CD14 antibody. The monocyte (1×10^6 /ml) was subsequently cultured in 24-well plates (Greiner Bio-One GmbH, Frickenhausen) in complete RPMI-1640 medium. The following cytokines were used: 100 ng/ml human granulocyte-macrophage colony-stimulating factor (GM-CSF) and 50 ng/ml of recombinant human IL-4 (both from Sigma) for 5 days. One-half of the culture volume was replaced with fresh medium and cytokines every 2 days. On day 5, fresh whole medium was added and four different maturation conditions were tested: 1) TNF- α (10 ng/ml); 2) PGE₁ (10^{-6} M); 3) TNF- α (10 ng/ml) plus PGE₁ (10^{-6} M) and 4) LPS from *E. coli* (100 ng/ml). Simultaneously, as a control one-step culture, some samples were also maintained without adding additional factors. Following 48 h DCs were harvested and analyzed by light microscopy and by flow cytometry

Immuno-phenotype analysis

DCs and monocytes were analyzed for expression of cell surface markers by single-color cytometry. Cells were harvested after Percoll gradient separation and after culturing for seven days. A total of 1×10^6 cells was incubated for 30 minutes on ice in 2% BSA containing phosphate-buffered saline (PBS) with the fluorescein isothiocyanate (FITC) - or phycoerythrin (PE) - conjugated mAb, or with control irrelevant isotype-matched mAb. The monoclonal antibodies used were: CD1a, CD80, CD86, CD83, CD40, CD14 and HLA-DR. HLA class II were analyzed by fluorescent-labeled Abs against HLA-DR. The stained cells were washed twice with PBS and fixed with 500 μ L of 2% paraformaldehyde in PBS. Then, cells were kept on ice, protected from light until flow cytometry analysis. Data

acquisition of 10,000 events was performed using a FACSort™ flow cytometer (Becton Dickinson, San Jose, CA) and analysis was performed using Cell-Quest (Becton Dickinson) software. Dendritic cell regions were electronically gated according to light and forward scatter properties to exclude cell debris, dead cells and contaminating lymphocytes and granulocytes.

Morphologic analysis

Morphologic analysis was performed on an Axioskop 2 plus, Zeiss microscope (Carl Zeiss from Brazil). A total of 2×10^4 cells MNCs cultured for 2 days and DCs cultured for 7 days were cytocentrifuged using a Cytospin-3 centrifuge (Shandon Southern Products, Astmoor, UK) on microscope slides. Then, cytopsins were air dried and stained with May-Grunwald-Giemsa before examining by light microscopy. Digital pictures were taken with a Zeiss Axioskop 2 plus (Carl Zeiss) microscope using a x100 NA 1.25 Plan-Apochromat oil lens and a AxionCam camera (Carl Zeiss). Digital images were subsequently converted into JPG format and imported into Adobe Photoshop 4.0 for editing and printing.

Statistical analysis

Descriptive statistics (arithmetic mean, median, and standard deviation) was used to describe each group of data.

Results

Enrichment of monocyte cells after Percoll gradient and morphological and phenotypical changes after culturing with GM-CSF plus IL-4

We obtained an enriched-CD14⁺ cell population after Percoll gradient centrifugation (Figure 1B). Starting with approximately $2-8 \times 10^8$ peripheral blood mononuclear cells,




Figure 1. Enrichment of monocyte cells after Percoll gradient and downregulation of CD14 expression on immature DCs. Representative flow cytometric analysis, displaying the phenotype of monocytes cells after Percoll gradient and the absence of CD14 positive cells after seven days in the presence of GM-CSF and IL-4. (A) FSC vs. SSC profile. The R1 gate corresponds to monocyte population; (B) The collected monocyte cells are on average 94% CD14 positive (day 0). The black histogram is labeled with control irrelevant mAb and grey histogram is stained with PE-labeled CD14 mAb; (C) The monocyte collected cells were analyzed by two-color cytometry for the expression of CD19 (B lymphocyte) and CD3 (T lymphocyte). The percentage of cells in each quadrant is listed, and (D) CD14 expression after 7 days in the presence of GM-CSF and IL-3. The immature DCs are CD14 negative. These data are from one representative experiment of a total of six performed

we typically ended up with $5-8 \times 10^7$ monocytes. Analysis by flow cytometry showed that the frequency of CD14⁺ cells was $91\% \pm 5$ and the lymphocyte contamination with CD3⁺/CD19⁺ cells was low (Figure 1C). Moreover, as expected, there is a strong decrease in the expression of CD14 after 7 days in the presence of GM-CSF plus IL-4 (Figure 1D) or other culture conditions (data not shown).

Morphologically, the CD14⁺ cells appear with the typical monocyte morphology, which includes small cells with a plasma cell-like morphology and characterized by an eccentric nucleus and without dendritic projection (Figure 2A). After 7 days in the presence of GM-CSF plus IL-4 the cells became larger and few cytoplasmic projections were observed which is characteristic of immature DCs (Figure 2B). These results corroborated with the analysis by FACS where it was observed that, compared with the starting cell population, cells that were cultured with GM-CSF and IL-4 for 7 days increased in size and granularity (data not shown).

The expression of antigens including HLA DR and CD86 are up-regulated in the starting cell population (median value of 81% and 97%, respectively) while CD1a, CD40, CD80 and CD83 antigens are not detected (median value between 0.7 and 1.5%). In the presence of GM-CSF plus IL-4 for 7 days is observed the differentiation of CD14⁺ cells into immature DCs as evaluated by FACS with a significantly higher expression of CD1a and CD80 (median of 34% and 9%, respectively).

The expression of HLA DR is retained in cells without any maturing agent while CD86 expression is decreased. Other phenotypes, including CD40 and CD83 showed a slightly higher expression compared with the starting cell population (Figure 3).

Effect of the addition of PGE₁ or TNF- α alone on phenotypical maturation of immature DCs

In the next series of experiments, we investigated the effect of PGE₁ and TNF- α alone on the phenotypical maturation of human MoDCs. At day 5 immature MoDCs were treated with PGE₁ or TNF- α stimuli for 48 hours, and




Figure 2. Morphological changes after culturing monocyte cells with GM-CSF plus IL-4 and in the presence or absence of different maturation stimuli. (A) Representative photographs of Wright-stained cytopins of enriched-CD14⁺ cells and immature and mature DC cultured for 7 days under different maturation stimuli: (A) enriched-CD14⁺ cell population; (B) immature-DCs; (C) TNF- α -DCs; (D) PGE₁-DCs; (E) TNF- α + PGE₁-DCs and (F) LPS-DCs. Magnification 100X.

the expression of maturity-related surface markers was analyzed by flow cytometry. As shown by flow cytometric analysis, in the presence of TNF- α , or PGE₁ alone the expression of CD1a⁺ is increased (median value of 82% and 94%, respectively, versus 34%). Related to the expression of the costimulatory CD80 molecule TNF- α -DCs had a higher level of expression (median of 40%) when compared to the levels of CD80 in immature DCs. On the contrary, CD80 expression could not be efficiently induced by DC exposed for 48 h to PGE₁ alone (median of 26%) when we compared with immature DCs (Figure 3).

Morphologically, under TNF- α (Figure 2C) or PGE₁




Figure 3. Greater expression of CD1a and CD80 costimulatory molecule in TNF- α + PGE₁-DC and LPS-DC than in TNF- α -DC and PGE₁-DC cultures. CD14⁺ monocyte-derived DCs were cultured with GM-CSF + IL-4. At day 5 fresh medium was added for 2 days under different stimuli. Cells were harvested and analyzed at day 7 by FACS after labeling with the isotype controls and indicated mAbs. Histograms show profiles of isotype controls (in grey) and monoclonal Abs (in black). Gates were set to include cells with large FSC and high SSC for DCs in the absence or presence of different maturing agents. Ten thousand gated events were collected for each analysis. Numbers indicate the percentage of CD expression. Data shown are representative of 3 to 6 experiments performed. The number of each DC culture conditions performed is indicated above each treatment

(Figure 2D), the cells exhibited an irregular shape and multiple cytoplasmic processes in many directions that typify dendritic cells. These results corroborated with the analysis by FACS where it was observed that the forward – and side – scatter distribution were higher than those of immature DCs, suggesting an increase in their size and granularity properties (data not shown).

The influence of TNF- α or PGE₁ on the expression of other antigens was also observed. As shown in Figure 3 under TNF- α treatment the expressions of HLA DR and CD86 remained similar to untreated DCs (median of 79% versus 82%, and 69% versus 61%, respectively), while the expressions of CD40 and CD83 were higher (median of 27% versus 12%, and 22% versus 4%, respectively). Similarly, phenotypic analysis of DCs under PGE₁ treatment showed

that the expression of HLA DR remained similar to untreated DCs (median of 78% versus 82%), and the expression of CD40 was slightly higher (median of 18% versus 12%). However, the expression of CD86 was downregulated (median of 31% versus 61%) and the expression of CD83 could not be stimulated (median of 4%) in both DC cultures, in the presence or absence of PGE₁.

Taken together, these data indicated that TNF- α or PGE₁ can increase the expression of CD1a 2.4 and 2.7 times, respectively, more than DC cultures in the absence of the maturing agent. However, for other costimulatory or accessory molecules (CD80, CD86, CD83 and CD40) TNF- α was more potent in the induction of the expression than PGE₁, suggesting that additional maturation factors are essential for obtaining efficiently matured DCs.

The presence of PGE₁ plus TNF- α has similar effect on phenotypical maturation of immature DCs compared to LPS

In the third series of experiments, we investigated the effect of TNF- α in combination with PGE₁ on the phenotypic maturation of human CD14⁺ derived-DCs (Mo-DCs). At day 5, immature Mo-DCs were treated with TNF- α plus PGE₁ stimuli for 48 hours, and the expression of maturity-related surface markers was analyzed by flow cytometry. Consistent with a previous work, DCs exposed to TNF- α plus PGE₁ have a higher expression of costimulatory and accessory molecules, CD80 and CD86 than DCs stimulated with TNF- α or PGE₁ alone.¹³ Moreover, CD1a showed an elevated expression. As shown by flow cytometry analysis in the presence of TNF- α plus PGE₁ the expression of CD1a and CD80 were elevated appreciably when compared with untreated-DCs (median of 90% and 79%, respectively, versus 34% and 9%). Also, as expected HLA DR and CD86 expression remained high and similar to untreated-DCs (median of 70% and 81%, respectively, versus 82% and 61%). Therefore, on the contrary to PGE₁ treatment where a decrease of CD86 expression (median of 14%) was observed the combination TNF- α and PGE₁ cooperate to activate the expression of CD86 (median of 70%). Surprisingly, TNF- α plus PGE₁ treated-DCs did not show significant increases of CD40 and CD83 expression compared to untreated or TNF- α -DCs and PGE₁-DCs (median of 28% and 19%, respectively, versus 12% and 4% for untreated-DCs; versus 27% and 22% for TNF- α -DCs and versus 12% and 4% for PGE₁-DCs). These results can be explained by DC-culture conditions (see comments on discussion) or by induction of a specific subset of dendritic cells.

Morphologically, under TNF- α plus PGE₁ treatment (Figure 2D) the cells exhibited a shape similar to TNF- α treated-DCs or PGE₁ treated-DCs with an irregular shape and multiple cytoplasmic processes in many directions that typify dendritic cells.

We next explored the relevance for the observed enhancement of DC maturation in the presence of TNF- α plus PGE₁. At day 5, immature CD14⁺-derived DCs were treated with LPS stimuli for 48 hours, and the expression of maturation-related surface markers was analyzed by flow cytometry. In LPS-DCs there were no significant differences in the levels of the expressions of CD1a, CD80, CD86 and CD83 compared to TNF- α plus PGE₁-DCs (median of 81%, 97%, 98% and 21% versus 90%, 79%, 81% and 19%, respectively, $p > 0.05$). Sequential analysis of other antigens showed that, the expression of HLA DR and CD40 has a more pronounced effect in the presence of LPS compared to TNF- α plus PGE₁ treatment (median of 97% and 67% versus 70% and 28%, respectively).

Thus, CD14⁺-derived DCs treated with TNF- α + PGE₁ display phenotypic mature characteristics for CD1a, CD80

and CD86 molecules similar to LPS-treated DCs and higher than their TNF- α treated-DC or PGE₁ treated-DC or untreated-DC counterparts.

Discussion

A variety of strategies to generate DCs are currently under investigation and there has been an increasing need to define the most promising candidate therapies for clinical studies. At present, most of the preclinical studies use DCs generated from monocytes isolated after adherence in culture flasks or from monocytes isolated after depleting lymphocyte cells with an immune magnetic column. Thus, the enriched-CD14⁺ monocyte cell population is differentiated into DCs in a two-step culture. In the first step GM-CSF and IL-4 promote the differentiation of immature monocyte derived DCs (iDCs) and in the second step pro-inflammatory factors induce the terminal maturation of DCs.^{12-13,21,24,26-28}

The studies described here have two proposes, first to establish a low cost and highly efficient technique to obtain an enriched-CD14⁺ monocyte cell population and second to perform a systematic comparison of the phenotypical maturation of DCs generated from different maturing agents that have been used in clinical assays.

The adherence of PBMCs in culture plates for two hours at 37°C could be considered the "gold standard" to isolate monocyte cell populations from progenitor PBMCs. However, the contamination with lymphocytes may be high. On the other hand, the second approach, which consists of using an immune magnetic column, is too expensive for daily routine. In this study we obtained a CD14⁺ enriched cell population by performing Percoll gradient from PBMCs. The results of FACS analysis of the recovered cells indicate that 91% \pm 5% were CD14⁺ cells and the content of cells expressing T and B markers were low. Additionally, these cells strongly express HLA DR and CD86 and lack expression of CD1a, CD40, CD80 and CD83.

We further observed that when these cells are stimulated *in vitro* with GM-CSF and IL-4 the cells can survive and enter cell cycles for *in vitro* DC development generating a typical iDC phenotype as they acquired CD1a and CD80 (median of 34% and 9%, respectively) while loosing CD14 expression. Moreover, the expression of HLA DR is retained, while CD86 expression decreases.

The question about which is the most efficient cocktail of cytokines to produce mature DCs has been addressed previously by several laboratories. In these studies, the presence of exogenous prostaglandins E₂ or E₁ enhanced the TNF- α induced maturation of DCs as analyzed by morphology, phenotype, ability to stimulate the allogeneic mixed leukocyte reaction and induction of IL-12 production.^{13,23,29} Also, the bacterial lipopolysaccharide (LPS) is known to be an inflammatory stimulus and has been shown to activate DCs, as well as, whole pathogens or other

components of microorganisms (e.g. dsRNA, CpG DNA and toxins,²⁹⁻³⁰).

However, our study is uniquely extensive in that we performed a systematic comparison with the yield of all spectra of DC markers that have been used to address the DC maturation before and after being exposed to four different maturing agents, including TNF- α , PGE₁, TNF- α plus PGE₁ and LPS.

Consistent with other studies,^{13,23,29} we show that TNF- α or PGE₁ alone are capable of inducing the maturation of DCs. Our TNF- α -treated DCs or PGE₁-treated DCs displayed higher expressions of CD1a⁺ compared with untreated DCs (median value of 82% and 94%, respectively, versus 34%) and some differences were found between both treatments. Analysis of the costimulatory and accessory molecules CD80, CD86, CD40 and CD83 showed a higher level after TNF- α treatment compared with PGE₁ treatment (median value of 40%, 78%, 27% and 22% versus 26%, 13%, 4% and 4%, respectively). However, studies by Steinbrink *et al.*¹³ demonstrated that PGE₁-treated DCs are CD1a⁺ and display higher expressions of CD80, CD86, CD40 and CD83 (81%, 80%, 50% and 55%, respectively). One possible explanation for this discrepancy is the differences in the culture conditions chosen. Steinbrink *et al.*¹³ favored X-VIVO 15 + 1% autologous plasma + GM-CSF + IL-4 for 7 days followed by the maturation with PGE₁ for 2 days. As reported by Jonuleit *et al.*,²¹ conceivably X-VIVO-cultured cells show a maturer activation/differentiation stage in comparison to RPMI-cultured cells, which may need additional signals, or a longer time in cultures. These authors also detected lower expressions of CD83 in PGE₁-treated DCs or TNF- α -treated DCs under RPMI conditions, while Lee *et al.*²³ obtained matured DCs with a higher expression of this CD marker on day 9 in cultured cells with RPMI conditions after TNF- α treatment. On the other hand, our TNF- α -treated DCs are CD1a⁺, and in agreement with a previous work this proinflammatory cytokine up-regulates the MHC class I expression as well as immune proteasome and TAP molecules at the cell surface of several Melanoma cell lines³¹ suggesting that TNF- α treatment is critical for an efficient immune response.

Moreover, considering that our TNF- α plus PGE₁-treated DCs show a three to five fold higher expression of CD80, CD40 and CD83 (median of 79%, 28% and 19%, respectively) as well as CD1a⁺ remaining highly expressed (median of 90%) together with the fact that these data are comparable to DCs generated using LPS *in vitro* we therefore suggest that the combination TNF- α + PGE₁ might be useful for generating *ex-vivo* DCs for efficient processing and presentation of antigens and therefore could be used as a cellular vaccines. LPS is known to be a potent stimulator of DC maturation³² however it has not been approved for clinical use because it can induce substantial toxicity. Further functional evaluation of these mature DCs is warranted.

Also, these three maturing agents, PGE₁, TNF- α and LPS, mediate their effects by distinct mechanisms: a) PGE₂, a member of the same PGE₁ family, mediates its effect on monocytoïd cells via 4 G protein-coupled receptors (EP1, EP2, EP3 and EP4) two of which mediate their signal through elevated cyclic adenosine monophosphate (cAMP, 33-34); b) TNF- α mediates its effects via CD134 and CD137 receptors; the latter has been shown to be expressed on follicular dendritic cells³⁵ and c) LPS mediates its effect on DC activation via TLR4 specific receptors on the surface of the DC.³⁶ The exact downstream signaling responses are not clearly understood, but these distinct receptors suggest distinct targeted genes and may also explain the differences observed among DCs generated *ex-vivo*.

Further studies to elucidate the molecular mechanism involved in the maturation process of DCs is essential not only to understand the biology of DCs but also to optimize dendritic cell immunotherapy in humans.

Resumo

*Células dendríticas (CDs) são células apresentadoras de antígenos altamente eficientes para a imunização contra patógenos e antígenos tumorais. A obtenção de CDs maturis tem sido descrita por diferentes métodos. Portanto, a escolha do método mais apropriado para gerar CDs em cultura de sete dias é pré-requisito essencial para as estratégias imunoterápicas. Aqui relatamos um método de obtenção de uma população enriquecida em monócitos de doadores de sangue e comparamos a maturação das CDs sob o estímulo de quatro agentes. Uma população de monócitos, com pureza de 91% ± 5, foi obtida de 15 doadores. A população monocitária foi mantida em cultura por cinco dias com GM-CSF e IL-4. No 5º dia, após diferentes condições de maturação, foram analisadas as modificações morfológicas e fenotípicas. Nossos estudos demonstram que o TNF- α ou o PGE₁ por si só podem induzir a expressão de CD1a de 2.4 a 2.7 vezes, respectivamente, mais do que culturas de CDs com ausência dos agentes de maturação. Alternativamente, para com outras moléculas coestimuladoras ou acessórias (CD80, CD86, CD83 e CD 40) o TNF- α foi mais potente na expressão do que o PGE₁, embora na presença de ambos o efeito seja mais pronunciado. A maturação fenotípica sob TNF- α + PGE₁ pode ser comparável ao LPS, concluindo que o TNF- α + PGE₁ pode ser útil para geração *ex-vivo* de CDs e útil para protocolos de vacinação celular. Avaliação funcional das CDs é recomendável. Rev. bras. hematol. hemoter. 2006;28(2):89-96.*

Palavras-chave: Células dendríticas; monócitos; Percoll; maturação; imunoterapia.

Acknowledgments

We thank Dr. Rita Viu Carrara for help in morphological analysis of DCs, Fabiana Rossetto de Moraes for help in FACS analysis and Sandra Navarro Bresciani for her expert assistance in figure design.

References

1. Banchereau J, Steinman L. Dendritic cells and the control of immunity. *Nature* 1998; 392:245-52.
2. Banchereau J, Briere F, Caux C, *et al.* Immunobiology of dendritic cells. *Annu Rev Immunol* 2000;18:767-811.
3. Sozzani, S, Allavena P, Vecchi A, *et al.* Chemokines and dendritic cell traffic. *J Clin Immunol* 2000;20:151-60.
4. Guernonprez P, Valladeau J, Zitvogel L, *et al.* Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. *Ann Rev Immunol* 2002;20:621-667.
5. Dhodapkar MV, Bhardwaj N. Active immunization of human with dendritic cells. *J Clin Immunol* 2000;20:167-74.
6. Gunzer M, Janich S, Varga G, *et al.* Dendritic cells and tumor immunology. *Sem Immunol* 2001;13:291-302.
7. Fonteneau JF, Larsson M, Bhardwaj N. Interactions between dead cells and dendritic cells in the induction of antiviral CTL response. *Cur Opin Immunol* 2002;14:471-7.
8. Quimones M, Ahuja SK, Melby PC, *et al.* Preformed membrane-associated stores of interleukin (IL)-12 are a previously unrecognized of bioactive IL-12 that is mobilized with minutes of contact with an intracellular parasite. *J Exp Med* 2000;192:507-16.
9. Richards JO, Ampel NM, Galgiani JN, *et al.* Dendritic cells pulsed with *Coccidioides immitis* lysate induce antigen-specific naive T cell activation. *J Inf Diseases* 2001;184:1.220-24.
10. Zheng M, Shellito JE, Marrero L, *et al.* CD4+ T cell-independent vaccination against *Pneumocystis carinii* in mice. *J Clin Invest* 2001; 108:1.469-74.
11. Zheng Z, Takahashi M, Narita M, *et al.* Generation of dendritic cells from adherent-cells of cord blood by culture with granulocyte-macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor- α . *J Hemat Stem Res* 2000;9:453-64.
12. Suen Y, Lee SM, Aono F, *et al.* Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC. *Cytotherapy* 2001;3:365-72.
13. Steinbrink, K, Paragnik L, Jonulcit H, *et al.* Induction of dendritic cell maturation and modulation of dendritic cell-induced immune responses by prostaglandins. *Arch Dermatol Res* 2000;292:437-45.
14. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. *J Exp Med* 1994;179(4):1.109-18.
15. Metcalf D. Multi-CSF-dependent colony formation by cells of a murine haemopoietic cell line: specificity and action of multi-CSF. *Blood* 1985; 65(2):357-62.
16. Verhasselt V, Buelens C, Willems F, *et al.* Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. *J Immunol* 1997;158:2.919-25.
17. Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. *Trends Immunol* 2002;23(6): 301-4.
18. Phipps RP, Stein SH, Roper RL. A new view of prostaglandin E regulation of the immune response. *Immunol Today* 1991;12(10):349-52.
19. Zelle-Rieser C, Ramoner R, Artner-Dworzak E, *et al.* Human monocyte-derived dendritic cells are deficient in prostaglandin E2 production. *FEBS Letters* 2002;511:123-6.
20. Bennett S, Por SB, Stanley ER, Breit SN. Monocyte proliferation in a cytokine-free, serum system. *J Immunol Methods* 1992;153:201-12.
21. Jonuleit H, Kuhn U, Muller G, *et al.* Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. *Eur J Immunol* 1997;27 (12):3.135-42.
22. Kalinski P, Schuitemaker JH, Hilkens CM, *et al.* Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation. *J Immunol* 1998. 15:161(6):2.804-9.
23. Lee AW, Truong T, Bickham K *et al.* A clinical grade cocktail of cytokines and PGE(2) results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy Vaccine 2002;20 Suppl 4:A8-A22.
24. Scandella E, Men Y, Gillesen S, *et al.* Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. *Blood* 2002;100:1.354-61.
25. de Almeida MC, Silva AC, Barral A, *et al.* A simple method for human peripheral blood monocyte isolation. *Mem Inst Oswaldo Cruz* 2000; 95(2):221-3.
26. Palucka KA, Taquet N, Sanchez-Chapuis F, *et al.* Dendritic cells as the terminal stage of monocyte differentiation. *J Immunol* 1998;160 (9):4.587-95.
27. Cao H, Verge V, Baron C, *et al.* In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy. *J Hematotherapy Stem Cell Res* 2000;9(2):183-94.
28. Luft T, Jefford M, Luetjens P, *et al.* Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. *Blood* 2002; 100(4):1.362-72.
29. Sallusto F, Cella M, Danieli C, *et al.* Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. *J Exp Med* 1995;182(2):389-400.
30. Brightbill HD, Libraty DH, Krutzik SR, *et al.* Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. *Science* 1999;285(5428):732-6.
31. Hallermalm K, Seki K, Wei C, *et al.* Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface. *Blood* 2001;98(4):1.108-15.
32. Brunner C, Seiderer J, Schlamp A, *et al.* Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses *in vivo*. *J Immunol* 2000;165(11):6.278-86.
33. Breyer RM, Bagdassarian CK, Myers AS, *et al.* Prostanoid receptors: subtypes and signaling. *Ann Rev Pharmacol Toxicol* 2001;41:661-90.
34. Ikegami R, Sugimoto Y, Segi E, *et al.* The expression of prostaglandin E receptors EP2 and EP4 and their different regulation by lipopolysaccharide in C3H/HeN peritoneal macrophages. *J Immunol* 2001; 166(7):4.689-96.
35. Lindstedt M, Johansson-Lindbom B, Borrebaeck CA. Expression of CD137 (4-1BB) on human follicular dendritic cells. *Scand J Immunol* 2003; 57(4):305-10.
36. Schnare M, Barton GM, Holt AC, *et al.* Toll-like receptors control activation of adaptive immune responses. *Nature Immunol* 2001; 2(10):947-50.

Avaliação: Editor e dois revisores externos.

Conflito de interesse: não declarado

Recebido: 19/12/2005

Aceito após modificações: 09/02/2006

Recursos financeiros: Fundherp Foundation and grants from Fapesp (1998/14247-6) and CNPq (62.0019/99.9)